{
  "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
  "docSlug": "63ec8e773c9b43e7b033b64167026114",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 52,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes comparative charts for transduction efficiency and anti-exhaustion capability.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/17",
  "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
  "deckJsonHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c.json",
  "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.0078,
        "y": 0.0055
      },
      "kind": "chart",
      "text": "Tonic signaling (TNFa levels)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ffcfce6-e83e-47d8-9ccc-914453fcc439",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.0078,
        "y": 0.0033
      },
      "kind": "chart",
      "text": "Transduction efficiency comparison",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1196d90-db67-4371-84b0-b4281f9f6b2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.0078,
        "y": 0.0075
      },
      "kind": "chart",
      "text": "Anti-exhaustion capability (flow cytometry)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7319896-e72e-4268-be07-1835f26946b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.14,
        "y": 0.0033
      },
      "kind": "image",
      "text": "Mechanism of action diagram showing BCMA expressing cancer cell and NXC-201 CAR-T cell",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82ba8973-8f59-4291-9b42-f9ff5fb385ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.02,
        "y": 0.0074
      },
      "kind": "list",
      "text": "NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) produced by our N-GENIUS platform targeting B-cell maturation antigen (BCMA). High Overall Response Rates in AL Amyloidosis and Multiple Myeloma. First Outpatient CAR-T: Short CRS duration (median 2 days) starting on day 0. No Neurotoxicity, only 1 grade 3 CRS across 42 Multiple Myeloma patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3e3f91a-dc93-4551-afa7-39a24aca8ac8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.02,
        "y": 0.0092
      },
      "kind": "source-note",
      "text": "Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d241bb80-3f85-4360-ab79-c0a92a410388",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.17,
        "y": 0.0018
      },
      "kind": "title",
      "text": "NXC-201: FIRST BCMA CAR-T GENERATED BY THE N-GENIUS PLATFORM",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f10712c-c335-4bde-a0cf-e4992406dfb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 MoA: Next Generation CAR-T For Multiple Myeloma and AL Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7db0c54-acd5-4a91-930a-0fb17ddc4487",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 15,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "ec7f8eed-93e3-495e-a456-08be8d6fdcb8",
      "evidence": "NXC-201 entering large markets at a pivotal moment",
      "position": 1,
      "objective": "Why now for Immix Biopharma's therapies?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}